Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 6/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.34 |
| ▸ | TACR1 | P25103 | 3/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27738376 | 1.00 | MAN1B1 (0.35) | MAN1B1CD274PDCD1LG2PDCD1TACR1 | |
| SCHEMBL1777255 | 0.98 | DPP7 (0.37) | MAN1B1CD274PDCD1LG2PDCD1TACR1 | |
| SCHEMBL27738350 | 0.98 | DPP7 (0.37) | MAN1B1CD274PDCD1LG2PDCD1TACR1 | |
| SCHEMBL1776966 | 0.96 | CD274 (0.34) | MAN1B1CD274PDCD1LG2PDCD1TACR1 | |
| SCHEMBL27738375 | 0.96 | CD274 (0.34) | MAN1B1CD274PDCD1LG2PDCD1TACR1 | |
| SCHEMBL21309877 | 0.76 | — | — | |
| SCHEMBL21309879 | 0.76 | — | — | |
| SCHEMBL18844896 | 0.76 | DPP7 (0.40) | DPP7LMNA | |
| SCHEMBL28775666 | 0.75 | ADH1B (0.40) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL1775537 | 0.75 | ADH1B (0.40) | CD274PDCD1LG2PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023708-A1 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-22 | — | — | US | claimed |
| EP-1943217-A1 | COMPOUNDS COMPRISING A LACTAM OR A LACTAM DERIVATIVE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2008-07-16 | — | — | EP | claimed |
| WO-2007048595-A1 | COMPOUNDS COMPRISING A LACTAM OR A LACTAM DERIVATIVE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA, S.A. (BE) | 2007-05-03 | — | — | WO | claimed |
| US-7943605-B2 | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses | UCB PHARMA S.A. (BE) | 2011-05-17 | — | — | US | disclosed |
| US-20090023708-A1 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-22 | — | — | US | disclosed |
| EP-1943217-A1 | COMPOUNDS COMPRISING A LACTAM OR A LACTAM DERIVATIVE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048595-A1 | COMPOUNDS COMPRISING A LACTAM OR A LACTAM DERIVATIVE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA, S.A. (BE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023708-A1 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses | COASY, FURIN, PEPD | MAN1B1 537/4885CD274 3017/4885PDCD1LG2 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.